Preventing RSV in infants in France
Part of Infections clinical trials.
This trial studies ways to prevent RSV infections in newborns. If you are a parent who gave birth in France between October 2024 and January 2025, you may be able to help researchers learn how to better protect babies from RSV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You can read and understand French well enough to read an information leaflet and fill out a questionnaire.
- You gave birth in mainland France between October 1, 2024 and January 31, 2025.
- Your baby was born alive and at full term (37 weeks or more of pregnancy).
- You agree to participate in the study (no objection).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how RSV (a common virus that can affect breathing) leads to illness in young children who come to the doctor with ear infections and/or breathing symptoms. It may help doctors better understand the “burden” RSV causes in both home/outpatient and hospital settings.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
This study tests whether a second dose of the RSV vaccine during a new pregnancy protects you and your baby from RSV. If you received the RSVpreF or Abrysvo vaccine in a past pregnancy, you may be able to join.
This study tracks viruses that cause sudden colds and flu-like illnesses during winter months in France. Researchers collect information from patients seen by participating doctors to better understand which respiratory viruses are circulating and help prepare for future outbreaks.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.